JPWO2020227563A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020227563A5 JPWO2020227563A5 JP2021566284A JP2021566284A JPWO2020227563A5 JP WO2020227563 A5 JPWO2020227563 A5 JP WO2020227563A5 JP 2021566284 A JP2021566284 A JP 2021566284A JP 2021566284 A JP2021566284 A JP 2021566284A JP WO2020227563 A5 JPWO2020227563 A5 JP WO2020227563A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- compound
- solvate
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 15
- 239000012453 solvate Substances 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962845119P | 2019-05-08 | 2019-05-08 | |
| US62/845,119 | 2019-05-08 | ||
| US201962884588P | 2019-08-08 | 2019-08-08 | |
| US62/884,588 | 2019-08-08 | ||
| PCT/US2020/031925 WO2020227563A1 (en) | 2019-05-08 | 2020-05-07 | Jak inhibitors |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022532877A JP2022532877A (ja) | 2022-07-20 |
| JPWO2020227563A5 true JPWO2020227563A5 (https=) | 2023-05-16 |
| JP2022532877A5 JP2022532877A5 (https=) | 2023-05-16 |
| JP7617030B2 JP7617030B2 (ja) | 2025-01-17 |
Family
ID=73051620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021566284A Active JP7617030B2 (ja) | 2019-05-08 | 2020-05-07 | Ｊａｋ阻害剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11136329B2 (https=) |
| EP (1) | EP3966209A4 (https=) |
| JP (1) | JP7617030B2 (https=) |
| KR (1) | KR102916168B1 (https=) |
| CN (1) | CN114269734B (https=) |
| AU (1) | AU2020267661A1 (https=) |
| BR (1) | BR112021022380A2 (https=) |
| CA (1) | CA3139277A1 (https=) |
| IL (1) | IL287876A (https=) |
| MX (1) | MX2021013602A (https=) |
| SG (1) | SG11202112362YA (https=) |
| TW (1) | TWI865525B (https=) |
| WO (1) | WO2020227563A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7617030B2 (ja) | 2019-05-08 | 2025-01-17 | ビマラン バイオサイエンシーズ，インク． | Ｊａｋ阻害剤 |
| KR20220051351A (ko) | 2019-08-08 | 2022-04-26 | 비말란 바이오사이언스즈, 인크. | Jak 억제제 |
| CN114644633B (zh) * | 2020-12-18 | 2026-02-03 | 北京诺诚健华医药科技有限公司 | 杂环类jak抑制剂 |
| KR102637915B1 (ko) * | 2021-06-25 | 2024-02-19 | 한국화학연구원 | 유비퀴틴 프로테오좀 경로를 통해 비티케이 분해작용을 가지는 신규한 이작용성 헤테로사이클릭 화합물과 이의 용도 |
| WO2023107705A1 (en) | 2021-12-10 | 2023-06-15 | Incyte Corporation | Bicyclic amines as cdk12 inhibitors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200802685B (en) | 2005-09-30 | 2009-10-28 | Vertex Pharma | Deazapurines useful as inhibitors of janus kinases |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | 諾華公司 | 吡咯并嘧啶化合物及其用途 |
| EP2108019A2 (en) | 2007-01-30 | 2009-10-14 | Biogen Idec MA, Inc. | 1-h-pyrazolo[3,4b]pyrimidine derivatives and their use as modulators of mitotic kinases |
| UY31631A1 (es) | 2008-02-06 | 2009-09-30 | Nuevos derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino, sales de los mismos, procesos para su preparacion, composiciones farmacéuticas que los comprenden y aplicaciones | |
| US9242987B2 (en) | 2009-10-20 | 2016-01-26 | Cellzome Limited | Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors |
| BR112012027803A2 (pt) | 2010-04-30 | 2016-08-09 | Cellzome Ltd | compostos de pirazol como inibidores de jak |
| US8637529B2 (en) | 2010-06-11 | 2014-01-28 | AbbYie Inc. | Pyrazolo[3,4-d]pyrimidine compounds |
| WO2012143320A1 (en) * | 2011-04-18 | 2012-10-26 | Cellzome Limited | (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors |
| WO2013041605A1 (en) * | 2011-09-20 | 2013-03-28 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors |
| WO2014001973A1 (en) | 2012-06-29 | 2014-01-03 | Pfizer Inc. | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS |
| RU2719477C2 (ru) | 2015-06-22 | 2020-04-17 | Оно Фармасьютикал Ко., Лтд. | Соединение, ингибирующее brk |
| CN108864057B (zh) * | 2017-05-16 | 2020-03-31 | 山东大学 | 含有4-氨基吡唑结构的jak与hdac双靶点抑制剂及其制备方法和应用 |
| JP7617030B2 (ja) | 2019-05-08 | 2025-01-17 | ビマラン バイオサイエンシーズ，インク． | Ｊａｋ阻害剤 |
| KR20220051351A (ko) | 2019-08-08 | 2022-04-26 | 비말란 바이오사이언스즈, 인크. | Jak 억제제 |
| BR112022005608A2 (pt) | 2019-09-25 | 2022-09-06 | Vimalan Biosciences Inc | Inibidores de jak |
-
2020
- 2020-05-07 JP JP2021566284A patent/JP7617030B2/ja active Active
- 2020-05-07 WO PCT/US2020/031925 patent/WO2020227563A1/en not_active Ceased
- 2020-05-07 KR KR1020217040186A patent/KR102916168B1/ko active Active
- 2020-05-07 CN CN202080050268.XA patent/CN114269734B/zh active Active
- 2020-05-07 SG SG11202112362YA patent/SG11202112362YA/en unknown
- 2020-05-07 EP EP20801611.3A patent/EP3966209A4/en active Pending
- 2020-05-07 AU AU2020267661A patent/AU2020267661A1/en active Pending
- 2020-05-07 BR BR112021022380A patent/BR112021022380A2/pt unknown
- 2020-05-07 CA CA3139277A patent/CA3139277A1/en active Pending
- 2020-05-07 MX MX2021013602A patent/MX2021013602A/es unknown
- 2020-05-07 US US16/869,433 patent/US11136329B2/en active Active
- 2020-05-08 TW TW109115406A patent/TWI865525B/zh active
-
2021
- 2021-11-07 IL IL287876A patent/IL287876A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL291345B1 (en) | IL-17A modulators and uses thereof | |
| WO2015054960A1 (zh) | 痛风治疗药Lesinurad的制备方法及Lesinurad中间体 | |
| JP2008543970A5 (https=) | ||
| RU2015138964A (ru) | Полициклические модуляторы рецептора эстрогена и их применения | |
| JP2021523200A5 (https=) | ||
| JP2018504437A5 (https=) | ||
| JP2015502387A5 (https=) | ||
| JP2016530210A5 (https=) | ||
| JPWO2020227563A5 (https=) | ||
| RU2004134559A (ru) | 4-замещенные имидазол-2-тионы и имидазол-2-оны в качестве агонистов альфа - 2в и альфа-2с адренэргических рецепторов | |
| HRP20130902T1 (hr) | PIRIDOPIRIMIDINONSKI INHIBITORI PI3Kalfa | |
| UA45303C2 (uk) | N-піперидино-5-/4-хлорфеніл/-1-/2,4-дихлорфеніл/-4-метилпіразол-3-карбоксамід або його солі, або їх сольвати, спосіб його одержання та фармацевтична композиція на їх основі | |
| JP2013507355A (ja) | キサンチンオキシダーゼ阻害剤として効果的な新規化合物、その製造方法及びそれを含有する医薬組成物 | |
| JP2022141692A5 (https=) | ||
| JP2016530209A5 (https=) | ||
| JP2005535731A5 (https=) | ||
| TW200946514A (en) | Activator for peroxisome proliferator-activated receptor | |
| AU2014279113A1 (en) | 4-alkynyl imidazole derivative and medicine comprising same as active ingredient | |
| JP2015535847A5 (https=) | ||
| HRP20160523T1 (hr) | Antikancerozni steroidni laktoni, nezasićeni na položaju 7(8) | |
| AU2010279354A1 (en) | Sphingosine-1-phosphate receptor agonists | |
| JP5269795B2 (ja) | カンナビノイドｃｂ１受容体アンタゴニストとしてのヘテロアリール−ピラゾール誘導体 | |
| JPWO2020163778A5 (https=) | ||
| JP2018535261A5 (https=) | ||
| CN103237793A (zh) | 具有多发性骨髓瘤的治疗效果的吡唑化合物 |